Nkarta Inc (OQ:NKTX)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 1150 Veterans Boulevard
Tel: N/A
Website: https://www.nkartatx.com
IR: See website
Key People
Paul J. Hastings
President, Chief Executive Officer, Director
Alyssa Levin
Chief Financial and Business Officer
Ralph Brandenberger
Chief Technical Officer
James Trager
Chief Scientific Officer
David Shook
Chief Medical Officer
Alicia J. Hager
Corporate Secretary, Chief Legal Officer
Business Overview
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of patients with autoimmune diseases or hematologic malignancies. It is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. Both product candidates enable an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies. Its NKX019 oncology program is based on the potential to treat a variety of B-cell malignancies by targeting the CD19 antigen that is reliably expressed on these types of cancerous cells. Its NKX101 program is designed to enhance the power of innate NK cell biology to detect and kill cancerous cells.
Financial Overview
For the three months ended 31 March 2024, Nkarta Inc revenues was not reported. Net loss decreased 4% to $29.5M. Lower net loss reflects Research and development - Balancing val decrease of 4% to $23M (expense), Stock-based Compensation in SGA decrease of 19% to $2.2M (expense), General and administrative - Balancing decrease of 3% to $5.4M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.63 to -$0.58.
Employees: 150 as of Mar 31, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $36.85M as of Mar 31, 2024
Annual revenue (TTM): $0.00M as of Mar 31, 2024
EBITDA (TTM): -$118.62M as of Mar 31, 2024
Net annual income (TTM): -$116.20M as of Mar 31, 2024
Free cash flow (TTM): -$117.41M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 70,467,620 as of Apr 15, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.